Courtesy of Benzinga.
Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson to be invalid and entered judgment in favor of Boston Scientific.
As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific’s PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146. The patents relate to the use of a drug on a drug-eluting stent.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
